Uremia aggravates left ventricular remodeling after myocardial infarction

American Journal of Nephrology

Volumn 32, Issue 1, 2010, Pages 13-22

  Dikow, Ralf ^a   Schmidt, Ulrike ^a   Kihm, Lars P ^a   Schaier, Matthias ^a   Schwenger, Vedat ^a   Gross, Marie Luise ^a   Katus, Hugo A ^a   Zeier, Martin ^a   Hardt, Stefan E ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Hypertrophy; Myocardial infarction; Remodeling; Renal failure

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CAPILLARY DENSITY; CELL DENSITY; CLINICAL ASSESSMENT; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE EXACERBATION; ECHOCARDIOGRAPHY; FOLLOW UP; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE SIZE; HEART MUSCLE CAPILLARY; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; IMMUNOHISTOLOGY; MALE; NONHUMAN; PARTIAL NEPHRECTOMY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RAT; UREMIA; ANIMAL; BIOPSY; BLOOD PRESSURE; CORONARY ARTERY BLOOD FLOW; DISEASE MODEL; ECHOGRAPHY; FIBROSIS; HEART MUSCLE; HEART VENTRICLE REMODELING; HYPERTROPHY, LEFT VENTRICULAR; METABOLISM; MORBIDITY; MYOCARDIAL INFARCTION; PATHOLOGY; PHYSIOLOGY; RISK FACTOR; SPRAGUE DAWLEY RAT;

ANIMALS; BIOPSY; BLOOD PRESSURE; BODY WEIGHT; COLLAGEN TYPE IV; CORONARY CIRCULATION; DISEASE MODELS, ANIMAL; ECHOCARDIOGRAPHY; FIBROSIS; HYPERTROPHY, LEFT VENTRICULAR; MALE; MORBIDITY; MYOCARDIAL INFARCTION; MYOCARDIUM; MYOCYTES, CARDIAC; RATS; RATS, SPRAGUE-DAWLEY; RISK FACTORS; UREMIA; VENTRICULAR REMODELING;

COLLAGEN TYPE 4;

EID: 77952302498     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000313846     Document Type: Article

References (38)

1. Michaud CM, Murray CJ, Bloom BR: Burden of disease - implications for future research. JAMA 2001;285:535-539.
2. Deedwania PC: The key to unraveling the mystery of mortality in heart failure: an integrated approach. Circulation 2003; 107: 1719-1721.
3. White HD, Norris RM, Brown MA, Brandt PW, Whitlock RM, Wild CJ: Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation 1987;76:44-51.
4. Garg R, Packer M, Pitt B, Yusuf S: Heart failure in the 1990s: evolution of a major public health problem in cardiovascular medicine. J Am Coll Cardiol 1993;22:3A-5A.
5. Pfeffer MA, Braunwald E: Ventricular remodelling after myocardial infarction. Experimental observations and clinical implications. Circulation 1990;81:1161-1172.
6. Rouleau JL, de Champlain J, Klein M, Bichet D, Moye L, Packer M, Dagenais GR, Sussex B, Arnold JM, Sestier F, et al: Activation of neurohumoral systems in postinfarction left ventricular dysfunction. J Am Coll Cardiol 1993;22:390-398.
7. Buss SJ, Backs J, Kreusser MM, Hardt SE, Maser-Gluth C, Katus HA, Haass M: Spi- ronolactone preserves cardiac norepineph-rine reuptake in salt-sensitive Dahl rats. Endocrinology 2006;147:2526-2534.
8. Sarnak ML, Levey AS, Schoolwerth AC, et al: Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003;108:2154-2169.
9. Lindner A, Charra B, Sherrard DJ, Scribner BH: Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 1974;290:697-701.
10. Foley RN, Parfrey PS, Sarnak MJ: Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 1998;9:S16-S23.
11. Herzog CA, Ma JZ, Collins AJ: Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med 1998; 339: 799-805.
12. Stack AG, Bloembergen WE: A cross-sectional study of the prevalence and clinical correlates of congestive heart failure among incident US dialysis patients. Am J Kidney Dis 2001; 38: 992-1000.
13. Banerjee D, Ma JZ, Collins AJ, Herzog CA: Long-term survival of incident hemodialysis patients who are hospitalized for congestive heart failure, pulmonary edema, or fluid overload. Clin J Am Soc Nephrol 2007; 2: 1186-1190.
14. Dikow R, Kihm LP, Zeier M, Kapitza J, Tornig J, Amann K, Tiefenbacher C, Ritz E: Increased infarct size in uremic rats: reduced ischemia tolerance? J Am Soc Nephrol 2004; 15:1530-1536.
15. Dikow R, Wasserhess C, Zimmerer K, Kihm LP, Schaier M, Schwenger V, Hardt S, Tiefen-bacher C, Katus H, Zeier M, Gross LM: Effect of insulin and glucose infusion on myocar-dial infarction size in uremic rats. Basic Res Cardiol 2009; 104: 571-579.
16. Hardt SE, Geng YJ, Montagne O, Asai K, Hong C, Yang GP, Bishop SP, Kim SJ, Vatner DE, Seidman CE, Seidman JG, Homcy CJ, Vatner SF: Accelerated cardiomyopathy in mice with overexpression of cardiac G(s)al-pha and a missense mutation in the alpha-myosin heavy chain. Circulation 2002; 105: 614-620.
17. Nabokov AV, Amann K, Wessels S, Munter K, Wagner J, Ritz E: Endothelin receptor antagonists influence cardiovascular morphology in uremic rats. Kidney Int 1999;55:512-519. (Pubitemid 29082877)
18. Levin A, Singer J, Thompson CR, Ross H, Lewis M: Prevalent left ventricular hypertrophy in the predialyis population: identifying opportunities for intervention. Am J Kidney Dis 1996;27:347-354.
19. Johnstone LM, Jones CL, Grigg LE, Wilkinson JL, Walker RG, Powell HR: Left ventricular abnormalities in children, adolescents and young adults with renal disease. Kidney Int 1996; 50:998-1006.
20. Foley RN, Parfrey PS, Harnett JD, Kent GM, Martin CJ, Murray DC, Barre PE: Clinical and echo cardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 1995;47:186-192.
21. Stewart GA, Gansevoort RT, Mark PB, Rooney E, McDonagh TA, Dargie HJ, Stuart R, Rodger C, Jardine AG: Electrocardio-graphic abnormalities and uremic cardio-myopathy. Kidney Int 2005; 67: 217-226.
22. Silberberg JS, Barre PE, Prichard SS, Snider-man AD: Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int 1989; 36:286-290.
23. Mall G, Rambausek M, Neumeister A, Koll-mar S, Vetterlein F, Ritz E: Myocardial interstitial fibrosis in experimental uremia - implications for cardiac compliance. Kidney Int 1988; 33: 804-811.
24. Mall G, Huther W, Schneider J, Lundin P, Ritz E: Diffuse intermyocardiocytic fibrosis in uraemic patients. Nephrol Dial Transplant 1990; 5: 39-44.
25. Amann K, Wiest G, Zimmer G, Gretz N, Ritz E, Mall G: Reduced capillary density in the myocardium of uremic rats - a stereological study. Kidney Int 1992;42:1079-1085.
26. Amann K, Breitbach M, Ritz E, Mall G: Myo-cyte/capillary mismatch in the heart of uremic patients. J Am Soc Nephrol 1998;9:10181022.
27. Amann K, Tyralla K, Gross ML, Schwarz U, Tornig J, Haas CS, Ritz E, Mall G: Cardio-myocyte loss in experimental renal failure: prevention by ramipril. Kidney Int 2003; 63:1708-1713.
28. Kennedy DJ, Vetteth S, Periyasamy SM, Kanj M, Fedoroya L, Khouri S, Kahaleh MB, Xie Z, Malhotra D, Kolodkin NI, Lakatta EG, Fe-dorova OV, Bagrov AY, Shapiro JI: Central role for the cardiotonic steroid marinobu-fagenin in the pathogenesis of experimental uremic cardiomyopathy. Hypertension 2006;47: 488-495.
29. Zoccali C, Benedetto FA, Mallamaci F, Tri-pepi G, Giacone G, Cataliotti A, Seminara G, Stancanelli B, Malatino LS: Prognostic impact of the indexation of left ventricular mass in patients undergoing dialysis. J Am Soc Nephrol 2001;12:2768-2774.
30. Golomb E, Nyska A, Schwalb H: Occult car-diotoxicity - toxic effects on cardiac isch-emic tolerance. Toxicol Pathol 2009; 37: 572593.
31. Ferdinandy P, Schulz R, Baxter GF: Interaction of cardiovascular risk factors with myo-cardial ischemia/reperfusion injury, preconditioning, and postconditioning. Pharmacol Rev 2007; 59: 418-458.
32. Ravingerova T, Matejikova J, Neckar J, An-delova E, Kolar F: Intrinsic defensive mechanisms in the heart: a potential novel approach to cardiac protection against ischemic injury. Mol Cell Biochem 2007; 297: 111-120.
33. Francis J, Weiss RM, Wei SG, Johnson AK, Felder RB: Progression of heart failure after myocardial infarction in the rat. Am J Physi-ol Reg Integ 2001;281:R1734-R1745.
34. Knowlton AA, Connelly CM, Romo GM, Mamuya W, Apstein CS, Brecher P: Rapid expression of fibronectin in the rabbit heart after myocardial infarction with and without reperfusion. J Clin Invest 1992; 89: 10601068.
35. Kennedy DJ, Elkareh J, Shidyak A, Shapiro AP, Smaili S, Mutgi K, Gupta S, Tian J, Morgan E, Khouri S, Cooper CJ, Periyasamy SM, Xie Z, Malhotra D, Fedorova OV, Bagrov AY, Shapiro JI: Partial nephrectomy as a model for uremic cardiomyopathy in the mouse. Am J Physiol Renal Physiol 2008; 294:F450-F454.
36. Tian J, Shidyak A, Periyasamy SM, Haller S, Taleb M, El-Okdi N, Elkareh J, Gupta S, Gohara S, Fedorova OV, Cooper CJ, Xie Z, Malhotra D, Bagrov AY, Shapiro JI: Spiro-nolactone attenuates experimental uremic cardiomyopathy by antagonizing marinobu- fagenin. Hypertension 2009; 54:1313-1320.
37. Fletcher PJ, Pfeffer JM, Pfeffer MA, Braun- wald E: Effects of hypertension on cardiac performance in rats with myocardial infarction. Am J Cardiol 1982; 50: 488-496.
38. Cooper-DeHoff R: Rethinking lower BP goals for diabetics with documented coronary artery disease - findings from the International Verapamil SR - Trandolapril Study (INVEST). ACC 2010, abstract.